| http://www.w3.org/ns/prov#value | - The Company intends to use the net proceeds from this offering to partially finance our Phase 3 clinical trial for our leading drug candidate, Menerba???, and for general corporate purposes, including capital improvements for manufacturing capacity, working capital and other Menerba non-clinical and clinical trials.
|
